ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "randomized trials"

  • Abstract Number: 028 • 2020 Pediatric Rheumatology Symposium

    A Randomized, Double-blind, Placebo-controlled Study of Anakinra in Pediatric and Adult Patients with Still’s Disease

    Laura Schanberg1, Peter Nigrovic 2, Ashley Cooper 3, Winn Chatham 4, Shoghik Akoghlanian 5, Namrata Singh 6, C. Egla Rabinovich 7, Akaluck Thatayatikom 8, Alysha Taxter 9, Jonathan Hausmann 10, Milan Zdravkovic 11, Sven Ohlman 11, Henrik Andersson 11, Susanna Cederholm 12, Gunilla Huledal 11, Rayfel Schneider 13 and Fabrizio De Benedetti 14, 1Duke Children's Hospital & Health Center, Durham, North Carolina, 2Boston Children's Hospital, Boston, Massachusetts, 3Children's Mercy Kansas City, Kansas City, 4University of Alabama at Birmingham, Birmingham, 5Nationwide Children's Hospital, Columbus, 6University of Iowa Hospitals and Clinics, Iowa, Iowa, 7Duke University Hospital, Durham, 8University of Florida, Gainesville, 9Wake Forest Baptist Medical Center, Winston-Salem, 10Division of Immunology, Boston Children's Hospital; Rheumatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, 11Sobi, Stockholm, Sweden, 12Stockholm, Sweden, 13The Hospital for Sick Children, Toronto, Canada, 14Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesu', Rome, Italy

    Background/Purpose: Adult-onset Still’s disease (AOSD) and systemic juvenile idiopathic arthritis (SJIA) are rare systemic disorders of auto-inflammatory nature. There is a growing understanding that SJIA…
  • Abstract Number: 2412 • 2019 ACR/ARP Annual Meeting

    Use of Minimal Important Difference (MID) in Randomized Clinical Trials of Pain in Osteoarthritis

    Lavalley Michael1, Matthew Parkes 2, Daniel White 3, Stephan Reichebach 4, Timothy McAlindon 5 and David Felson 6, 1Boston University, Boston, 2University of Manchester, Manchester, England, United Kingdom, 3University of Delaware, Newark, DE, 4University of Bern, Bern, Switzerland, 5Tufts Medical Center, Boston, MA, 6Boston University School of Medicine, Department of Rheumatology, Boston

    Background/Purpose: Minimal important differences (MID), based on within-subject evaluation of attaining  an improvement in a continuous outcome such as a pain scale, are important for…
  • Abstract Number: 2414 • 2019 ACR/ARP Annual Meeting

    Efficacy and Safety of Abatacept in Patients with Early Active Primary Sjögren’s Syndrome – Open-label Extension Phase of a Randomized Controlled Phase III Trial

    Jolien van Nimwegen1, Esther Mossel 1, Robin Wijnsma 1, Greetje van Zuiden 1, Konstantina Delli 1, Alja Stel 1, Bert van der vegt 1, Erlin Haacke 1, Lisette Olie 1, Leonie Los 1, Gwenny Verstappen 1, Sarah Pringle 1, Fred Spijkervet 1, Frans Kroese 1, Arjan Vissink 1, Suzanne Arends 2 and Hendrika Bootsma 3, 1University Medical Center Groningen, University of Groningen, Groningen, Netherlands, 2Dept. of Rheumatology and Clinical Immunology - University Medical Center Groningen (UMCG), University of Groningen, Groningen, Netherlands, 3University of Groningen, Groningen, Netherlands

    Background/Purpose: Abatacept (CTLA-4-Ig) targets the CD80/CD86:CD28 co-stimulatory pathway required for full T-cell activation and T-cell dependent activation of B-cells. The Abatacept Sjögren Active Patients phase…
  • Abstract Number: 2820 • 2018 ACR/ARHP Annual Meeting

    Sustained Clinical Remission after Discontinuation of Infliximab with a Raising Dose Strategy in Patients with Rheumatoid Arthritis (RRRR study): A Randomized Controlled Trial

    Yoshiya Tanaka1, Koji Oba2,3, Takao Koike4,5, Nobuyuki Miyasaka6, Tsuneyo Mimori7, Tsutomu Takeuchi8, Shintaro Hirata9, Eiichi Tanaka10, Hidekata Yasuoka11, Yuko Kaneko8, Kosaku Murakami7, Tomohiro Koga12, Kazuhisa Nakano13, Koichi Amano14, Kazuyasu Ushio15, Tatsuya Atsumi16, Masayuki Inoo17, Kazuhiro Hatta18, Shinichi Mizuki19, Shohei Nagaoka20, Shinichiro Tsunoda21, Hiroaki Dobashi22, Nao Horie3 and Norihiro Sato3, 1University of Occupational and Environmental Health, Kitakyushu, Japan, 2Interfaculty Initiative in Information Studies, The University of Tokyo, Tokyo, Japan, 3Clinical Research and Medical Innovation Center, Hokkaido University Hospital, Sapporo, Japan, 4Hokkaido Medical Center for Rheumatic Diseases, Sapporo, Japan, 5NTT Sapporo Medical Center, Sapporo, Japan, 6Department of Medicine and Rheumatology, Tokyo Medical and Dental University, Tokyo, Japan, 7Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, 8Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, 9Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital, Hiroshima, Japan, 10Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, 11Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, tokyo, Japan, 12Center for Bioinformatics and Molecular Medicine, Nagasaki University, Graduate School of Biomedical Sciences, Nagasaki, Japan, 13The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, 14Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Saitama, Japan, 15Ushio Clinic, Osaka, Japan, 16Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan, 17Utazu hospital, Utatsu-cho, Japan, 18Department of General Medicine, Tenri Hospital, Tenri, Japan, 19Center for Rheumatic Diseases, Matsuyama Red Cross Hospital, Matsuyama, Japan, 20Department of Rheumatology, Yokohama Minami Kyosai Hospital, Yokohama, Japan, 21Division of Rheumatology Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan, 22Division of Endocrinology and Metabolism, Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Kagawa University, Miki-cho, Japan

    Background/Purpose: Infliximab (IFX), a TNF inhibitor, is one of the most widely used biological disease-modifying antirheumatic drugs. Recent studies indicated that baseline levels of serum…
  • Abstract Number: 1476 • 2017 ACR/ARHP Annual Meeting

    Effect of Treat-to-Target Tocilizumab- and Methotrexate-Based Strategies on Health-Related Quality of Life in Newly Diagnosed Rheumatoid Arthritis Patients: Results of the U-Act-Early Trial

    Xavier M Teitsma1, Johannes WG Jacobs1, Paco MJ Welsing2, Attila Pethö-Schramm3, Michelle EA Borm4, Jacob M. van Laar5, Floris PJ Lafeber5 and Johannes W.J. Bijlsma2, 1Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, 2Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, 3F. Hoffmann-La Roche, Basel, Switzerland, 4Beneluxlaan 2a, Roche Nederland BV, Woerden, Netherlands, 5Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands

    Background/Purpose: Patient-reported outcomes are, in addition to other efficacy and safety related outcomes, important reflections of effectiveness and adverse effects of a therapy. The Outcomes…
  • Abstract Number: 2475 • 2017 ACR/ARHP Annual Meeting

    Clinical Remission in Subjects with Rheumatoid Arthritis Treated with Subcutaneous Tocilizumab As Monotherapy or in Combination with Methotrexate or Other Synthetic Dmards: A Real-World Clinical Trial

    Raimon Sanmartí1, Emilio Martín-Mola2, João E. Fonseca3, Douglas J. Veale4, Alejandro Escudero-Contreras5 and Carlos M Gonzalez6, 1Rheumatology Service, Hospital Clínic de Barcelona, Barcelona, Spain, 2Hospital La Paz, Madrid, Spain, 3Rheumatology Research Unit, Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal, Lisbon, Portugal, 4Rheumatology, St. Vincent's University Hospital, Dublin 4, Ireland, 5Rheumatology service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, 6Rheumatology, Hospital General Universitario Gregorio Marañón, Madrid, Spain

    Background/Purpose: the primary objective of this study was to assess the 24-week efficacy and safety of subcutaneous (SC) tocilizumab (TCZ) 162 mg weekly (qw) as…
  • Abstract Number: 15 • 2017 Pediatric Rheumatology Symposium

    An Internet-based Self-management Program for Adolescents with Juvenile Idiopathic Arthritis – A Randomized Controlled Trial

    Jennifer N. Stinson1, Sarah Campillo2, Tania Cellucci3, Paul Dancey4, Ciarán M. Duffy5, Janet Ellsworth6, Brian Feldman7, Adam Huber8, Nicole Johnson9, Patrick McGrath8, Alan Rosenberg10, Natalie J. Shiff11, Lynn R. Spiegel12, Shirley M.L. Tse13, Lori Tucker14, J. Charles Victor15 and Stephanie Luca16, 1Anesthesia and Pain Medicine, The Hospital for Sick Children, Toronto, ON, Canada, 2Montreal Children's Hospital, Montreal, QC, Canada, 3Pediatrics/Rheumatology, McMaster Children's Hospital, Hamilton, ON, Canada, 4Pediatrics, Janeway Children's Hospital, St. John's, NL, Canada, 5Children's Hospital of Eastern Ontario and University of Ottawa, Ottawa, ON, Canada, 6University of Alberta, Edmonton, AB, Canada, 7Department of Rheumatology, Hospital for Sick Children, Toronto, ON, Canada, 8IWK Health Centre, Halifax, NS, Canada, 9Pediatrics, University of Calgary, Alberta Children's Hospital, Calgary, AB, Canada, 10Pediatrics, University of Saskatchewan, Saskatoon, SK, Canada, 11University of Florida, Gainesville, FL, 12Rheumatology/Pediatrics, The Hospital for Sick Children, Toronto, ON, Canada, 13Rheumatology, The Hospital for Sick Children and University of Toronto, Toronto, ON, Canada, 14Pediatric Rheum/Rm K4-120, BC Childrens Hospital, Vancouver, BC, Canada, 15University of Toronto, Toronto, ON, Canada, 16The Hospital for Sick Children, Toronto, ON, Canada

    Background/Purpose: Juvenile Idiopathic Arthritis (JIA) is a common chronic childhood illness associated with physical and emotional symptoms that can negatively impact health-related quality of life…
  • Abstract Number: 18 • 2016 ACR/ARHP Annual Meeting

    The Impact of Disease-Related and Contextual Factors on Work Outcomes in Chronic Inflammatory Arthritis Patients Treated with Biologics: A Systematic Review

    Jenny Shu1, Panos Lambiris2 and Claire Bombardier3, 1Department of Rheumatology, University of Toronto, Toronto, ON, Canada, 2University Health Network, Toronto, ON, Canada, 3Toronto General Hospital Research Institute, Toronto, ON, Canada

    Background/Purpose:  Biological therapy has been shown to have a positive effect on work outcomes, such as work participation and/or work disability in patients with chronic…
  • Abstract Number: 764 • 2016 ACR/ARHP Annual Meeting

    Atacicept: Integrated Safety Profile from Phase II Randomized Placebo-Controlled Studies in Autoimmune Diseases

    Patricia Fraser, Wai Chin and Amy Kao, EMD Serono, Billerica, MA

    Background/Purpose:  Atacicept, a recombinant fusion protein, targets both BLyS (B lymphocyte stimulator) and APRIL (a proliferation-inducing ligand), B cell activating factors involved in the pathogenesis…
  • Abstract Number: 867 • 2016 ACR/ARHP Annual Meeting

    Termination of Tocilizumab-Treatment in Giant Cell Arteritis: Follow-up of Patients after the RCT (ClinicalTrials.gov registration number: NCT01450137)

    Sabine Adler1, Stephan Reichenbach2, Stefan Kuchen3, Felix Wermelinger4, Diana Dan4, Michael Seitz4 and Peter M. Villiger4, 1Rheumatology, Immunology, Allergology, University Hospital Bern, Bern, Switzerland, 2Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland, 3Rheumatology, Immunology, and Allergology, University of Bern, Bern, MD, Switzerland, 4Department of Rheumatology, Immunology and Allergology, University Hospital Bern, Bern, Switzerland

    Background/Purpose:  
  • Abstract Number: 9L • 2015 ACR/ARHP Annual Meeting

    A Randomized Double-Blind Trial of Abatacept and Glucocorticoids for the Treatment of Giant Cell Arteritis

    Carol A. Langford1, David Cuthbertson2, Steven R. Ytterberg3, Nader A. Khalidi4, Paul A. Monach5, Simon Carette6, Philip Seo7, Larry W. Moreland8, Michael Weisman9, Curry L. Koening10, Antoine G. Sreih11, Robert F. Spiera12, Carol McAlear13, Kenneth J. Warrington14, Christian Pagnoux6, Kathleen Maksimowicz-McKinnon15, Lindsy J. Forbess16, Gary S. Hoffman1, Renee Borchin17, Jeffrey Krischer17 and Peter A. Merkel18, 1Rheumatology, Cleveland Clinic, Cleveland, OH, 2Biostatistics and Informatics, Department of Pediatrics, University of South Florida, Tampa, FL, 3Rheumatology Division, Mayo Clinic, Rochester, MN, 4McMaster University, St Joseph's Healthcare Hamilton, Hamilton, ON, Canada, 5Rheumatology, Boston University School of Medicine, Boston, MA, 6Division of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, 7Division of Rheumatology, Johns Hopkins, Baltimore, MD, 8Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, 9Cedars-Sinai Medical Center, Los Angeles, CA, 10Division of rheumatology, George E. Wahlen Department of Veterans Affairs Medical Center Salt Lake City and University of Utah, University of Utah School of Medicine, Salt Lake City, UT, 11Department of Rheumatology, University of Pennsylvania, Philadelphia, PA, 12Rheumatology, Hospital for Special Surgery, New York, NY, 13Penn Vasculitis Center, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, 14Rheumatology, Mayo Clinic, Rochester, MN, 15Rheumatology, University of Pittsburgh, Pittsburgh, PA, 16Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, 17University of South Florida, Tampa, FL, 18Division of Rheumatology, University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Giant cell arteritis (GCA) is a large-vessel primary systemic vasculitis. Although glucocorticoids are effective in treating GCA, they are associated with substantial toxicity and…
  • Abstract Number: 972 • 2015 ACR/ARHP Annual Meeting

    A Phase 2b Study Evaluating the Efficacy and Safety of Subcutaneously Administered Tregalizumab in Subjects with Active Rheumatoid Arthritis (RA) Despite Treatment with Methotrexate (MTX)

    Ronald F. van Vollenhoven1, Edward C. Keystone2, Vibeke Strand3, Cesar Pacheco-Tena4, Jiri Vencovsky5, Frank Behrens6, Daniela Zipp7, Faiza Rharbaoui8, Ralf Wolter9, Rolf-Dietrich Tiemann10, Luise Knierim11, Rainer Schmeidl11, Xuefei Zhou12, Silke Aigner8,13, Benjamin Daelken14 and Andrea Wartenberg-Demand8,12, 1Department of Medicine, Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), The Karolinska Institute, Stockholm, Sweden, 2Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, 3Biopharmaceutical Consultant, Portola Valley, CA, 4Universidad Autónoma de Chihuahua, Chihuahua, Mexico, 5Institute of Rheumatology, Prague, Czech Republic, 6CIRI/Rheumatology & Fraunhofer TMP, Goethe University, Frankfurt, Germany, 7Landseinerstr 5, Biotest AG, Dreieich, Germany, 8Biotest AG, Dreieich, Germany, 9Corporate Clinical Research, L, Biotest AG, Dreieich, Germany, 10Data Management and Outsourcing, Biotest AG, Dreieich, Germany, 11Cooperate Drug Safety, Biotest AG, Dreieich, Germany, 12Cooperate Clinical Research, Biotest AG, Dreieich, Germany, 13Landsteinerstrasse 5, Biotest AG, Dreieich, Germany, 14Project Managerment Office, Biotest Pharmaceuticals Corporation, Boca Raton, FL

    Background/Purpose: In autoimmune diseases reduced numbers and functional impairment of regulatory T cells (Tregs) have been observed (1). Tregalizumab (BT-061) is a humanized, anti-CD4 mAb,…
  • Abstract Number: 1672 • 2015 ACR/ARHP Annual Meeting

    One-Year Safety of Sirukumab Monotherapy: Results from a Randomized, Double-Blind, Parallel-Group, Multicenter Study in Japanese Subjects with Moderate to Severe Rheumatoid Arthritis

    Tsutomu Takeuchi1, Hisashi Yamanaka2, Masayoshi Harigai3, Ryo Tamamura4, Yuchi Kato4, Yoshifumi Ukyo4, Toshikazu Nakano4, Takayuki Ota4, Benjamin Hsu5 and Yoshiya Tanaka6, 1Keio University School of Medicine, Tokyo, Japan, 2Dept. of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, 3Dept of Pharmacovigilance, Tokyo Medical and Dental University, Tokyo, Japan, 4Janssen Pharmaceutical K.K., Tokyo, Japan, 5Janssen Research & Development, LLC, Spring House, PA, 6The First Dept. of Internal Medicine, University of Occupational & Environmental Health, Kitakyusyu, Japan

    Background/Purpose: Interleukin-6 (IL-6) is a pleiotropic cytokine known for its proinflammatory functions. In rheumatoid arthritis (RA), increased concentrations of IL-6 may stimulate leukocyte recruitment to…
  • Abstract Number: 2541 • 2015 ACR/ARHP Annual Meeting

    Improving Adherence with Treat to Target in Rheumatoid Arthritis through a Learning Collaborative: Rationale and Design of the Traction Trial

    Daniel H. Solomon1, Sara Lee2, Agnes Zak2, Jen Agosti3, Asaf Bitton4, Liana Fraenkel5, Leslie Harrold6, Elena Losina7, Bing Lu8, Theodore Pincus9, Josef S. Smolen10 and Jeffrey N. Katz11, 1Rheumatology, Brigham and Women's Hospital, Boston, MA, 2Brigham and Women's Hospital, Boston, MA, 3JRA Consulting, Andover, MA, 4Medicine, Brigham and Women's Hospital, Boston, MA, 5Medicine, Yale University School of Medicine, New Haven, CT, 6Dept of Medicine, UMass Medical School, Worcester, MA, 7Orthopedics, Brigham and Women's Hospital, BU School of Public Health and Harvard Medical School, Boston, MA, 8Rheumatology Immunology & Allergy, Brigham & Women's Hospital, Boston, MA, 9Medicine-Rheumatology, NYU Hospital for Joint Diseases, New York, NY, 10Medical University of Vienna, Vienna, Austria, 11Brigham and Women's Hospital and Harvard Medical School, Boston, MA

    Background/Purpose:   Treat to target (TTT) is a recommended paradigm in the management of rheumatoid arthritis (RA).  However, various data sources suggest that TTT is…
  • Abstract Number: 2854 • 2015 ACR/ARHP Annual Meeting

    Long-Term Tolerability and Efficacy of Golimumab in Active Nonradiographic Axial Spondyloarthritis: Results from the Open-Label Extension of a Randomized, Double-Blind Study

    Désirée van der Heijde1, Maxime Dougados2, Walter Maksymowych3, Gina Bergman4, Sean P. Curtis4, Anjela Tzontcheva4, George Philip4, Susan Huyck4 and Joachim Sieper5, 1Leiden University Medical Center, Leiden, Netherlands, 2Paris-Descartes University, Paris, France, 3University of Alberta, Edmonton, AB, Canada, 4Merck & Co., Inc., Kenilworth, NJ, 5University Clinic Benjamin Franklin, Berlin, Germany

    Background/Purpose: The tolerability and efficacy of golimumab (GLM) as a treatment for nonradiographic axial spondyloarthritis (nr-axSpA) were recently investigated in a randomized, double-blind (DB), placebo…
  • 1
  • 2
  • 3
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology